PacBio continues to target compound annual revenue growth of 40% to 50% through 2026 based on a 2022 revenue base of $128.3M, representing a 2026 revenue target of over $500M. PacBio expects to share 2024 guidance on its fourth-quarter earnings conference call in February 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PACB:
- PacBio initiated with neutral view at Guggenheim, here’s why
- PacBio initiated with bullish view at Stephens, here’s why
- PacBio initiated with neutral view at Wolfe Research, here’s why
- PacBio initiated with neutral view at Wolfe Research
- PacBio announces retirement of Botstein from board of directors
